Quanterix 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Quanterix reported Q3 2026 revenue of $35 million, up 6.3% sequentially and down 13.1% from Q3 2025's reported $40.2 million.
- Management said that, excluding $2.4 million of Q3 2025 revenue from a terminated diagnostic development program and including $0.6 million of Akoya pre-acquisition revenue, the year-over-year revenue decline was 8.6%.
- Revenue improved across product categories, with Americas revenue up high teens percentage sequentially; EMEA was down sequentially, reflecting seasonally lower revenue, and APAC was roughly flat.
- Spatial revenue grew by a double-digit percent sequentially, with consumables at their second-highest level ever in Q3 and near record levels; Simoa revenue increased slightly sequentially, driven by instrument placements.
- Accelerator Lab bookings grew for the second consecutive quarter, with book-to-bill approaching 2x; Q3 Accelerator Lab revenue was about $2.9 million.
- GAAP gross profit and margin were $13.5 million and 38.6%; non-GAAP gross profit was $16.6 million, down 10% year over year, and non-GAAP gross margin was 47.4%, up 150 basis points.
- Q3 2026 operating expenses were $36 million; non-GAAP operating expenses were $35.4 million, down $2.8 million year over year. Net loss was $21.6 million, and adjusted EBITDA loss was $12.2 million.
- Cash usage was $16.2 million in Q3, and Quanterix ended the quarter with approximately $80.7 million in cash.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, everyone. Thank you for joining us, and welcome to Quanterix Corporation Third Quarter 2026 Earnings Call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Mary Conway, Investor Relations.
Please go- Thank you and good morning.
With me on today's call are Everett Cunningham, Quanterix's President and CEO, and Jason Faessler, Quanterix's Chief Financial Officer. Today's call is being recorded, and a replay of the call will be available on the Investors section of our website. During today's presentation, we will make forward-looking statements covered under the U.S. Private Securities Litigation Reform Act. These forward-looking statements are based on management's beliefs and assumptions as of today, November 9th, 2026. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, assumptions, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. To supplement our financial statements presented on a GAAP basis, we have provided certain non-GAAP financial measures.
These non-GAAP measures are used to evaluate our operating performance in a manner that allows for meaningful period-to-period comparison and analysis of trends in our business and our competitors. We believe that such measures are important in comparing current results with other periods' results and assessing our operating performance within our industry. Non-GAAP financial information presented herein should be considered in conjunction with, and not as a substitute for, the financial information presented in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures set forth in the presentation posted to our website and in the earnings release issued today. Finally, any percentage changes we discuss will be on a year-over-year basis unless otherwise noted. Now, I'd like to turn the call over to Everett Cunningham.
Everett? Thanks, Mary, and good morning, everybody.
You know, I'm happy to share that we exceeded our expectations for top-line performance in the third quarter, with sequential revenue growth of 6.3% and improvement across the business. These results reflect the hard work of our entire team. Our solid Q3 results are an important early proof point in our path to restoring growth. There's more. As shown on slide three, our commercial teams performed better across the board despite continued market softness, with strong sequential growth across all product categories and technology platforms. The Americas region posted the strongest improvement with high teens percentage growth. Spatial consumables were at a near-record level, demonstrating that our instrument install base is being utilized. We're pleased with these first elements of recovery at Quanterix, which are reversing the revenue decline from trend from last year.
Our Accelerator Lab grew bookings for the second consecutive quarter at a book-to-bill approaching 2x, and the new dedicated sales team is focused on building long-term relationships, including through our custom assay development services. We expanded the SIMOA menu with more neurology biomarkers, and our Spatial Content Innovation Engine released new spatial assays for our PhenoCycler. We doubled the number of LucentAD tests sold in Q3 from the prior quarter, as commercial partnerships are driving demand. New partnerships that I'll discuss later today position us to extend that growth. Now, with the foundation of these efforts, we now possess several critical catalysts for accelerating growth for Quanterix. These include the complete build-out of our senior leadership team includes Dr. Yuri Fesko as our first Chief Medical Officer.
Yuri's deep experience with large diagnostics companies in clinical and regulatory areas is already benefiting teams across the company with relevant and timely expertise. Jim Gute joined Quanterix in mid-August as our Chief Commercial Officer, bringing proven leadership to help drive improved execution in our commercial organization with rigor, discipline, and accountability. Our diagnostics team added important sales and marketing talent to the team, ready to leverage more opportunities for diagnostics revenue growth. Their efforts are supported by impactful insurance coverage that is growing. We are pleased with the decision by Florida's Medicaid administrator, as I'll discuss shortly, to approve coverage of blood-based biomarker testing for Alzheimer's disease, like LucentAD Complete, for 4 million Florida residents eligible for Medicaid as of November 1st. Innovation is emerging as a strategic lever for both SIMOA and Spatial teams.
Between recent assay and menu option launches and upcoming Plan X expansions, we're addressing real customer needs to drive greater use of our instrument install base, as we've already seen with our Q3 consumable growth. Spatial's Content Innovation Engine is targeting exciting new areas, including ones surrounding the hallmarks of cancer that I'll describe further. This is a great start, and we plan to actively build upon it. Turning to slide four, let's review our organizational priorities, the strategies driving our progress. The first element, and I've said this since I started back in January, is bringing a laser focus to improving our commercial execution. I just mentioned the discipline and rigor that Jim Gute is deploying within our commercial organization.
Our return to a product-based approach allows our sales team to bring their optimal skills and decades of market focus to each customer, whether that be in spatial, SIMOA, or our Accelerator Lab or diagnostics. Second, we're prioritizing the key areas in our strategic roadmap to accelerate growth. That means strengthening our position in ultrasensitive protein detection, which we're accomplishing through concrete steps like launching new assays and menu options, as I noted. Addressing customer needs effectively is critical to our growth in a competitive marketplace, along with advancing the in vitro diagnostics readiness of our HD-X platform that we expect will expand distribution opportunities for us. Third, we plan to leverage our diagnostics business, where the dedicated team is working hard under Geoff Albrecht's leadership to scale for growth by continuing to expand commercial partnerships and build networks and clinical credibility.
This is a critically important initiative for our company. Quanterix is a recognized leader in ultrasensitive protein detection, with differentiated capabilities across blood-based biomarkers and spatial tissue analysis. These technologies, enabled by their sensitivity, reproducibility, and high throughput performance, create significant near-term opportunities in diagnostics as healthcare increasingly prioritizes earlier detection and intervention. Now let me share some Q3 updates from our product teams in both SIMOA and spatial areas on slides five, six, and seven, where we show how we're addressing customer needs more directly and delivering innovation that will help speed up, expand, and improve their research efforts. On our SIMOA platform, we expanded our assay menu offering in Q3 by launching APOE4 proteotyping and IL-18 kits, enabling steady and important increase of new biomarkers for new research in Alzheimer's and other neurodegenerative diseases.
APOE4 variants have been linked to risk of Alzheimer's disease and serious side effects associated with anti-amyloid therapies. The SIMOA APOE4 proteotyping assay allows researchers to distinguish between non-carriers, heterozygotes, and homozygotes that are linked to an individual's risk status. The SIMOA IL-18 assay fills an emerging need to better understand the role of neuroinflammation in the onset and progression of Alzheimer's disease and has a broader application in inflammation and oncology. Importantly, our work on the planned submission of our 510(k) application for our HD-X instrument as an IVD remains on track, with our third-party contract manufacturer fully engaged as we plan to execute towards our goal of a 2027 submission. Lastly, new regulatory approvals will advance access to neurology biomarker testing in China based upon our HD-X and SR-X instruments and testing kits for four biomarkers.
Innovita Biological Technology Company, a leading Chinese diagnostics company, is broadening access to blood biomarker testing in China as part of our strategy to bring our SIMOA-powered diagnostic capabilities to large markets worldwide by working with strong regional commercial partners. In September, at the European Society for Spatial Biology meeting, we showcased significant progress in our Spatial Content Innovation Engine with the PhenoCode 2.0 molecular barcoding kit, now in full commercial release, enabling researchers to barcode virtually any antibody in applications spanning immuno-oncology, neuroscience, and other areas. Two other panels will ship early in 2027. One, the TIME panel, providing a broader view of the tumor immune microenvironment, and the other, the high-plex antibody drug conjugate, or ADC panel, that enables co-measurement of ADC target expression alongside tumor immune contexture within a single tissue section, addressing demand for combination biology readouts.
Our Accelerator Lab is accepting requests for custom ADC panel development, widening access to its ADC combination biology fully managed service for biopharma and translational teams. On slide seven, we illustrate how the hallmarks of cancer framework, shown on the right, is helping us build out and expand our spatial oncology panel offerings, including some recent new product launches that I mentioned. We see an excellent opportunity to continue to expand our offerings, covering more elements of the hallmarks of cancer, which are fundamental way of understanding cancer, and further increase our spatial consumable growth as we did in Q3. These new offerings and approaches underline our highly regarded scientific innovation and respond directly to customers' needs in the clinic and lab. We're excited about our new panels and technological advances, and we intend to maintain this pace to sustain our market leadership.
Traction in diagnostics business continues to build, setting a sound foundation for the strong growth that we anticipate in 2027. We are making impressive progress, establishing new meaningful collaborations, pushing forward on reimbursement, and positioning Quanterix to achieve our goal next year. Highlights as shown on slides eight and nine included. LucentAD tests more than double sequentially as we transform our diagnostics business into a larger, profitable element of Quanterix's profile. We are expanding across different end customers and areas within diagnostics. We have signed new commercial partnerships with two key clinical reference labs, Sherman Abrams in the New York, New Jersey tri-state area, and TruPath in Mississippi, spanning over 14 states across the U.S. Both partnerships will soon be operational, and we are delighted about the caliber of opportunities that we are going to pursue together, broadening the reach of our existing collaborations with other commercial partners.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
8 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
